October 4, 2021
Press release
EFPIA Japan(European Federation of Pharmaceutical Industries and Associations)

EFPIA Japan Patient Organization Support Program “PASE”
Fourth “PASE AWARD” winners decided
TOKYO – 30 September 2021 – EFPIA Japan (European Federation of Pharmaceutical Industries andAssociations) presented its Fourth PASE AWARD, selecting patient groups that particularly contributeto the evolution of Japan’s patient advocacy and offering grants totalling 1.45 million yen. For thefourth year, “addressing the challenges of the COVID-19 pandemic and creating connected,
supportive societies” was selected as the application theme. Recruitment of patient organizations'action plans started in May and applications from a total of 14 patient organizations were received by
July 16. This year the “Grand Award” has been given to two groups, and the “Honor Award” has been
given to three groups as below.

Fourth PASE AWARD winning organizations
AwardAward winning organization

Grand NPOAward Keep Mama Smiling

Overview of application / proposal

Expand support for long-term inpatient caregivers
who cannot leave the ward due to Covid19 infection
prevention

Grant(JPY)
500,000

Grand InstituteActivities to raise awareness of correct knowledge of500,000
Award Esophageal Cancer Survivors Sharings esophageal cancer and examination and prevention
Certified NPO
Honor
Disseminate information to promote social
Breast Cancer Patient Association
150,000
understanding of cancer
AwardKirara
Provide information for balancing treatment withHonor NPO
school/work and distribute stickers to notify the public of 150,000
Award Sagamihara Allergy Association
allergic symptoms
Honor NPO
Awareness activities to promote early access to the150,000
Award PanCAN Japan
treatment of pancreatic cancer
EFPIA Japan Chair Takahiko Iwaya said, "I would like to thank all the patient organizations thatapplied for the Fourth PASE AWARD. Patient group activities to support patients are becoming more
and more important in the face of various restrictions due to the pandemic caused by COVID-19 sincelast year. All the proposals received this time were very meaningful especially in these difficult times,
and the decision on the Grand Prize was extremely difficult. EFPIA Japan will continue to support theactivities of these patient groups to ensure that patients in Japan have access to the latest medicalcare.”

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017
Tel: +81-3-6417-2032 Fax: +81-3-6685-4870

About the EFPIA Japan Patient Organization Support Program “PASE”“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program
established in 2017 with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE wasconceived to further encourage patient group activities in Japan, and to support the healthcare
environment surrounding patients to evolve, so that it better reflects patients’ voices and patientneeds. As part of PASE, EFPIA Japan decided to conduct the PASE AWARDs, in which grants of 1.45
million yen this year will be awarded to organizations that contribute to the evolution of patientadvocacy (activities to protect patient rights).
About the Fourth “PASE AWARD”
Due to the fight against the novel virus that has been raging since last year, we are now required torestrict various aspects of our lives. Under such circumstances, many patients feel increasingly lonely,
and it has become even more important to improve the understanding of those around us, to connect
with society and other patients, and to communicate smoothly with doctors. For the Fourth PASE
AWARD, in light of the potential impact of these environmental changes on patients, “addressing thechallenges of the COVID-19 pandemic and creating connected, supportive societies” was selected as
the application theme. The Fourth PASE AWARD invited active patient groups with legal entity status
to submit plans between May 12 and July 16 to utilize the PASE grant in Japan. The draft plans werereviewed and selection was based on four evaluation criteria: “Having a clear purpose as a patientgroup and clear goals with KPIs”, “Showing concrete deliverables for achieving purpose in pastactivities”, “Having a specific implementation plan of activity for using grants (including how to usegrants)”, “Being able to cooperate in disseminating the results of activities using grants (Allowing for
posting on the EFPIA Japan website, notification and reporting on their own website)”. The twoorganizations that won the Grand Award will each be offered a grant of 500,000 yen and be invited toattend the presentation ceremony on October 13, 2021. The three groups that won the Honor Award
will be offered a grant of 150,000 yen. Details of the Fourth PASE AWARD presentation ceremony willbe shared separately.
The Fourth PASE Final Selection Committee Members


Mr. Takahiko Iwaya, EFPIA Japan Chair (Sanofi K.K.)

Mr. Yoshiaki Aono, EFPIA Japan Vice Chair (Nippon Boehringer Ingelheim Co., Ltd.)

Mr. Paul Lirette, EFPIA Japan Board Member (GlaxoSmithKline K.K.)

Mr. Kana Matsumura, EFPIA Japan Governance and Legal Committee Chair (Nippon Boehringer
Ingelheim Co., Ltd.)Mr. Takeo Nakayama (Kyoto University Faculty of Medicine, Professor of Health Informatics)

About EFPIA Japan
Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceuticalcompanies operating in Japan. In 2020, combined sales from the member companies accounted
for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is toEFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017
Tel: +81-3-6417-2032 Fax: +81-3-6685-4870
2

“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.

About the European Federation of Pharmaceutical Industries and Associations (EFPIA)EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents thepharmaceutical industry operating in Europe. Through its direct membership of 36 nationalassociations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies
committed to researching, developing and bringing new medicines to improve health and quality of lifearound the world
Details can be found below.
http://efpia.jp/ (EFPIA Japan)
http://www.efpia.eu (EFPIA)
Inquires to：Jun Saito
EFPIA Japan Public Relations Sub-committee incharge of PASE
1-23-1 Toranomon, Minato-ku, Tokyo105-6333
Toranomon Hills Mori Tower
Novartis Pharma K.K.
TEL: 080-7566-8852
Mail: jun.saito@novartis.com

Naomi Sakai
EFPIA Japan Patient committee in charge ofPASE
2-1-1 Osaki, Shinagawa-ku, Tokyo
141-6017
ThinkPark Tower
Nippon Boehringer Ingelheim Co., Ltd.
TEL: 03-6417-2489
Mail: naomi.sakai@boehringer-ingelheim.com

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017
Tel: +81-3-6417-2032 Fax: +81-3-6685-4870
3